Pharmacovigilance Risk Management Plan (RMP)

Explore the structure of the pharmacovigilance risk management plan, detailing its seven parts, the eight modules of part two (S1–S8), and the roles of post-authorisation safety studies and risk minimization.

This lecture outlines part i of the pharmacovigilance risk management plan, detailing active substance information, product overview elements, indications, dosage forms, and applicable EU authorisation procedures.

Examine safety specifications across eight modules (S1–S8), from epidemiology and non-clinical safety to clinical trial exposure and missing information, guiding post-authorisation experience and risk minimization planning.

Explore the pharmacovigilance plan in the RMP part III, detailing safety concerns characterization, risk minimization effectiveness, and routine versus additional post-authorisation safety studies.

Plan post-authorisation efficacy studies in part four, listing required studies and any imposed conditions on marketing authorisation, including conditional or exceptional circumstances; leave part four empty if none.

Explore part five of the risk management plan, detailing routine and additional risk minimization measures and their evaluation, with focus on SMPC, package leaflet, labeling, pack size, and legal status.

Part six summarizes the risk management plan, compiling key points from prior parts, and the summary on EPR or national websites highlights safety concerns, missing information, and pharmacovigilance.

Explore annexes to the pharmacovigilance risk management plan, detailing annexures 1 to 8, study protocols, adverse event follow-up forms, risk minimization data, and changes over time.

Examine risk minimization measures, including the selection of tools and effectiveness indicators. Review the four categories: educational materials, direct healthcare professional communication, pregnancy prevention programs, and controlled access programs.

Evaluate the effectiveness of risk minimization measures using three principles—focused evaluation, regular evaluation with planned time points, and evaluation of intended and unintended outcomes—plus post-authorisation safety studies.

Deliver timely, evidence-based safety information on new risks to medicines, guiding risk minimization and informed use by patients and healthcare professionals.

Master the pharmacovigilance risk management plan template by detailing product overview, safety specifications, pharmacovigilance plan, post-authorisation studies, risk minimization measures, and annexes within EU guidance and versioned documents.

Identify common sections between the pharmacovigilance risk management plan and the safety concerns report, including clinical trial exposure, post‑authorisation experience, identified risks, safety summaries, and risk minimization evaluation.

After completing this pharmacovigilance risk management plan (rmp) course, retrieve your certificate, share it on LinkedIn, access downloadable materials and qa options, and explore related pharmacovigilance courses.